Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-2203

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-2203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2203 9)

Label for Losartan Potassium 100 mg film coated tablets by NuCare Pharmaceuticals, Inc., containing 90 tablets. The label includes NDC 68071-2203-9, manufacturer information listing Vivimed Life Sciences Private Limited, and storage instructions at controlled temperature 59-86°F. It displays warnings to keep out of reach of children and notes the product is Rx only.*

FDA Label Image

Image002 (Image 01)

A line graph comparing the percentage of patients with the primary endpoint over study months, showing Atenolol (dotted line) and Losartan potassium (solid line). The graph includes an annotation of adjusted risk reduction of 13% with p=0.021.*

FDA Label Image

Image003 (Image 02)

A line graph comparing the percentage of patients with fatal and non-fatal strokes over study months between Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months up to 66, and the y-axis shows the percentage of patients. The graph indicates a 25% adjusted risk reduction with Losartan potassium (p=0.001) compared to Atenolol.*

FDA Label Image

Image004 (Image 03)

A forest plot chart comparing event rates and hazard ratios (95% CI) between Losartan Potassium and Atenolol across patient subgroups. It shows primary composite events and stroke (fatal/non-fatal) outcomes by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). The plot illustrates relative risk favoring either drug, with event rates in percentages for both treatments.*

FDA Label Image

Image005 (Image 04)

A line graph showing the percentage of patients with event versus months up to 48, comparing Losartan potassium and placebo groups. The graph indicates a risk reduction of 16.1% with a p-value of 0.022. Losartan potassium is represented by a solid line, placebo by a dotted line.*

FDA Label Image

Image001 (Structure)

Chemical structure diagram of the active ingredient Losartan Potassium, showing the molecular arrangement and potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.